Related Experiment Videos
Bromocriptine and dopaminergic function in Huntington disease
Neurology
|May 1, 1979
Summary
Low-dose bromocriptine improved Huntington disease symptoms by increasing cerebrospinal fluid homovanillic acid (HVA). Higher doses worsened symptoms and decreased HVA, suggesting a dose-dependent effect on dopamine pathways.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Huntington disease is a neurodegenerative disorder.
- Dopamine pathways are implicated in Huntington disease.
- Homovanillic acid (HVA) is a dopamine metabolite.
Purpose of the Study:
- To investigate the effect of bromocriptine on cerebrospinal fluid (CSF) homovanillic acid (HVA) levels in patients with Huntington disease.
- To explore the dose-dependent effects of bromocriptine on Huntington disease symptoms and HVA concentrations.
Main Methods:
- Assay of CSF HVA in 10 patients with Huntington disease.
- Administration of varying doses of bromocriptine.
- Clinical assessment of chorea severity.
- Correlation of clinical response with CSF HVA levels.
Main Results:
- Low-dose bromocriptine (<40 mg/day) led to clinical improvement and increased CSF HVA.
- Higher doses of bromocriptine worsened chorea and decreased CSF HVA.
- Bromocriptine exhibited a dose-dependent effect on dopamine pathways.
Conclusions:
- Low-dose bromocriptine may act as a partial dopamine antagonist in Huntington disease.
- High-dose bromocriptine may act as a direct dopamine receptor agonist.
- Bromocriptine's efficacy in Huntington disease is dose-dependent, influencing dopamine neurotransmission.